WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities. “Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” said Dr. Saadi. “I’ ...

WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. Bethel Fire Company, supporting the organization’s mission to protect the Warren Township community. The donations reflect Dr. Saadi’s continued commitment to supporting first responders and the Warren Township community. “On behalf of the Mt. Bethel Fi ...

Core Points - Tevogen Bio Holdings Inc. announced a significant donation of 230,000 shares from its Founder and CEO, Dr. Ryan Saadi, to the Warren Township Honorary Policemen's Benevolent Association [2][10] - The donation aims to support local community initiatives, including safety equipment for police officers and community welfare programs [3][6] Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing advanced technologies for developing life-saving therapies [11] - The company has a diverse pipeline that includes programs in virology, oncology, and neurology, leveraging its proprietary ExacTcell™ platform [12] Community Engagement - The donation reflects Tevogen's commitment to community responsibility and enhancing the safety of local law enforcement [9][8] - The funds will be allocated for critical equipment to improve the safety and effectiveness of police services in Warren Township [6][7]

WARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s Board of Directors and Professor Emeritus at Yale University, as he is honored in a new joint portrait commissioned by the Yale School of Medicine’s Program for Art in Public Spaces. The portrait celebrates the extraordinary, decades-long contributions of Dr. Patton and James Comer, MD, MPH, Maurice Falk Professor in the Chi ...

Core Viewpoint - Tevogen Bio Holdings Inc. emphasizes its commitment to capital-efficient operations and sustainable practices in the biotechnology industry, as highlighted in its quarterly report for Q3 2025 [1][8]. Financial Performance - The company reported a loss from operations of $5.7 million for Q3 2025, a 6% decrease compared to Q3 2024 [2][3]. - For the nine months ended September 30, 2025, the operating loss was $21.5 million, reflecting a 51% reduction compared to the same period in 2024 [2][3]. - Total operating expenses for Q3 2025 were $5.7 million, down from $6.1 million in Q3 2024 [3]. - Research and development expenses for Q3 2025 were $3.1 million, compared to $3.3 million in Q3 2024 [3]. - General and administrative expenses decreased to $2.6 million in Q3 2025 from $2.8 million in Q3 2024 [3]. Non-GAAP Financial Metrics - On a non-GAAP basis, the adjusted loss from operations was $2.5 million for Q3 2025, a 10% reduction from $2.8 million in Q3 2024 [5][6]. - For the nine months ended September 30, 2025, the adjusted loss from operations was $7.8 million, a 25% decrease from $10.4 million in the same period of 2024 [5][7]. Strategic Focus - The company aims to transition from traditional high-cost drug development to a more efficient model that emphasizes patient affordability while maintaining profitability [8]. - Tevogen is committed to scalable science and responsible execution, focusing on broad patient access in its pipeline for infectious diseases and oncology [8].

Core Insights - Tevogen Bio Holdings Inc. has been recognized in BINJE's BEST Health Care 2025 for its commitment to health equity and innovation in sustainable biopharma [1][2] - The company's focus is on developing affordable and safe T cell therapies for acute viral infections and cancers, utilizing its proprietary ExacTcell™ platform [2] Company Overview - Tevogen Bio is dedicated to advancing health equity by ensuring access to life-saving medications through a sustainable biopharma model [2] - The company operates a lean, capital-efficient structure that avoids licensing overhead by fully owning its core intellectual property [2] - Tevogen's CD8+ T cell therapies are designed to reduce manufacturing complexity and costs, aligning with U.S. healthcare priorities [2] Technological Advancements - The launch of Tevogen.AI aims to accelerate therapeutic discovery and development through advanced algorithms and partnerships with Microsoft and Databricks [2] Recognition and Community - Tevogen expresses gratitude to BINJE and congratulates other honorees in the health care sector for their achievements [3]

Core Insights - Tevogen Bio Holdings Inc. has been recognized in BINJE's BEST Health Care 2025 for its commitment to health equity and innovation in sustainable biopharma [1][2] - The company's focus is on developing affordable T cell therapies for acute viral infections and cancers, utilizing its proprietary ExacTcell™ platform [2] Company Overview - Tevogen Bio is dedicated to advancing health equity by ensuring access to life-saving medications through a sustainable biopharma model [2] - The company operates a lean, capital-efficient structure that avoids licensing overhead by fully owning its core intellectual property [2] - Tevogen's CD8+ T cell therapies are designed to reduce manufacturing complexity and costs, aligning with U.S. healthcare priorities [2] Technological Advancements - The launch of Tevogen.AI aims to accelerate therapeutic discovery and development through advanced algorithms and partnerships with Microsoft and Databricks [2] Recognition and Community - Tevogen expresses gratitude to BINJE and congratulates other honorees in the health care sector for their achievements [3]

Core Insights - Tevogen Bio Holdings Inc. reported a significant increase in institutional ownership of its common stock, with a 60% rise as of March 31, 2025, compared to December 31, 2024 [2] - Major contributors to this growth were Vanguard and BlackRock, which collectively increased their holdings by 151% [2] - A notable 73% of the 51 institutional investment managers holding Tevogen stock either increased or maintained their positions, indicating a strong influx of new investors [2][3] Company Developments - The increase in institutional ownership is viewed as a positive indicator of confidence in the company's fundamentals and long-term growth potential [3] - Tevogen is advancing its Tevogen.AI initiatives, including new patent activities and collaborations with Microsoft and Databricks, which are aimed at developing targeted therapies for cancers and infectious diseases [3] - The company plans to establish its own GMP cell manufacturing facility, further supporting its growth trajectory [3] Future Outlook - Tevogen will provide another update on institutional ownership following the next SEC reporting period, indicating ongoing transparency and engagement with investors [3]

Core Insights - Tevogen Bio Holdings Inc. has secured $1 million in funding to enhance its artificial intelligence-driven drug discovery program, Tevogen.AI [1][6] - The funding is part of a larger agreement with KRHP LLC, which could provide up to $10 million in non-dilutive funding, including $2 million received in January 2025 [2][6] - Tevogen.AI's recent patent publication for its machine learning technology aims to improve targeted therapies for cancers and infectious diseases [2] Financial Position - The company is well-capitalized, with access to a $36 million line of credit, ensuring it can execute its growth strategy effectively [3][6] - The total potential funding from KRHP LLC, including the recent $1 million, amounts to $10 million, which will support the advancement of Tevogen.AI [2][6] Strategic Focus - The funding will be utilized to accelerate Tevogen.AI's capabilities, focusing on enhancing target discovery, shortening development timelines, and improving treatment accessibility for large patient populations [2][6]

Core Insights - Tevogen Bio Holdings Inc. reported a 60% increase in institutional ownership of its common stock as of March 31, 2025, compared to December 31, 2024 [2] - Vanguard and BlackRock were the largest contributors to this growth, increasing their holdings by 151% [2] - 73% of the 51 institutional investment managers holding Tevogen stock either increased or maintained their positions, indicating a significant influx of new investors [2][3] Company Developments - The increase in institutional ownership is viewed as a sign of confidence in Tevogen's fundamentals and long-term growth potential [3] - Tevogen is advancing its Tevogen.AI initiatives, including new patent activity and collaborations with Microsoft and Databricks [3] - The company plans to establish its own GMP cell manufacturing facility, which is expected to enhance its capabilities in developing targeted therapies for cancers and infectious diseases [3] Future Outlook - Tevogen will provide another update on institutional ownership following the next SEC reporting period, indicating ongoing monitoring of investor sentiment [3]